Research & Development


恒康LOGO-en
API NamesIndicationSpecificationsRegulatory
SNAC / 9-Salcaprozate SodiumProtecct SemaglutideIN HOUSEDMF
L-lysineFor InjectionIN HOUSEDMF IN PROCESS
API NamesIndicationCAS No.Stage
AcalabrutinibMCL/CLL1420477-60-6Sample Available
Alogliptin BenzoateDiabetes850649-62-6Sample Available
AprocitentanHypertension1103522-45-7Pilot
Baloxavir MarboxilAnti-influenza1985606-14-1Pilot
ClascoteroneAcne Vulgaris19608-29-8Pilot
Daridorexant HClSleep Initiation and Maintenance Disorders1792993-84-0Sample Available
DelgocitinibAtopic Dermatitis1263774-59-9Sample Available
DoravirineAnti – HIV1338225-97-0Lab Stage
LemborexantSleep Initiation and Maintenance Disorders1369764-02-2Sample Available
ResmetiromMetabolic Dysfunction Associated Steatotic Liver Disease920509-32-6Sample Available
Rimegepant SulfateMigraine Disorders1374024-48-2Pilot
RotigotineAntiparkinsonian99755-59-6Sample Available
Sodium PicosulfateConstipation10040-45-6Pilot
TegoprazanGRED942195-55-3Pilot
Tenapanor HClIrritable Bowel Syndrome with Constipation1234365-97-9Lab Stage
Trelagliptin SuccinateDiabetes1029877-94-8Sample Available
VericiguatHeart Failure1350653-20-1Pilot
Viloxazine HClAttention Deficit Disorder with Hyperactivity35604-67-2Pilot
NOTE:  1) The products are not for patents covered area or countries.
2) The most intermediates are  available for listed APIs.

Research & Development

R & D
R&D2

Basing on such R&D innovations, Zhejiang Hengkang Pharmaceutical was certificated as National High and New Technology Enterprise in 2017.

R&D3
Scroll to Top